August 31st 2024
This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.